1381 related articles for article (PubMed ID: 18393148)
21. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
Castaman G; Federici AB; Rodeghiero F; Mannucci PM
Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
[TBL] [Abstract][Full Text] [Related]
22. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
23. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
24. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis of subtype 2B von Willebrand disease in a patient with 2A phenotype of plasma von Willebrand factor.
Gaucher C; de Romeuf C; Rauïs-Morret M; Corazza F; Fondu P; Mazurier C
Thromb Haemost; 1995 Apr; 73(4):610-6. PubMed ID: 7495067
[TBL] [Abstract][Full Text] [Related]
26. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.
Favaloro EJ
Blood Rev; 1999 Dec; 13(4):185-204. PubMed ID: 10741895
[TBL] [Abstract][Full Text] [Related]
27. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
[TBL] [Abstract][Full Text] [Related]
28. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance.
Enayat MS; Guilliatt AM; Lester W; Wilde JT; Williams MD; Hill FG
Br J Haematol; 2006 Jun; 133(6):664-6. PubMed ID: 16704444
[TBL] [Abstract][Full Text] [Related]
29. Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease.
Shihong I; Morris D; Konkle BA
Haemophilia; 2009 Jan; 15(1):131-4. PubMed ID: 18976254
[TBL] [Abstract][Full Text] [Related]
30. Type 2B Hiroshima: a variant of von Willebrand disease characterized by chronic thrombocytopenia and the presence of all von Willebrand factor multimers in plasma.
Takimoto Y; Imanaka F
Int J Hematol; 1999 Aug; 70(2):127-31. PubMed ID: 10497852
[TBL] [Abstract][Full Text] [Related]
31. Management of inherited von Willebrand disease in 2007.
Federici AB; Mannucci PM
Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
[TBL] [Abstract][Full Text] [Related]
32. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
33. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
Favaloro EJ
Semin Thromb Hemost; 2006 Sep; 32(6):566-76. PubMed ID: 16977567
[TBL] [Abstract][Full Text] [Related]
34. The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network.
Keeney S; Bowen D; Cumming A; Enayat S; Goodeve A; Hill M;
Haemophilia; 2008 Sep; 14(5):1099-111. PubMed ID: 18637846
[TBL] [Abstract][Full Text] [Related]
35. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and management of von Willebrand disease in Australia.
Favaloro EJ; Bonar R; Favaloro J; Koutts J
Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
[TBL] [Abstract][Full Text] [Related]
37. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
38. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
[TBL] [Abstract][Full Text] [Related]
39. Rethinking the diagnosis of von Willebrand disease.
Favaloro EJ
Thromb Res; 2011 Jan; 127 Suppl 2():S17-21. PubMed ID: 21193108
[TBL] [Abstract][Full Text] [Related]
40. Genetics of type 2B von Willebrand disease: "true 2B," "tricky 2B," or "not 2B." What are the modifiers of the phenotype?
Othman M; Favaloro EJ
Semin Thromb Hemost; 2008 Sep; 34(6):520-31. PubMed ID: 19085651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
